Is Immunocore Holdings plc (IMCR) Overvalued?
We dive into why Immunocore Holdings plc (IMCR) could be considered overvalued on 2026-08-06, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Commentary & Analysis
Why Immunocore Holdings plc’s (IMCR) Stock Is Up 5.98%
As of Wednesday, May 06, Immunocore Holdings plc’s IMCR share price has surged by 5.98%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
What You Need to Know About Immunocore Holdings plc's Q2 Earnings
Immunocore Holdings plc's fiscal Q2 earnings report was released on Wednesday, May 06. Let's dive in to see if (IMCR) missed or beat analyst's expectations.Tudor Pop
Why Immunocore Holdings plc’s (IMCR) Stock Is Down 5.93%
As of Thursday, March 05, Immunocore Holdings plc’s IMCR share price has dipped by 5.93%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
What You Need to Know About Immunocore Holdings plc's Q1 Earnings
Immunocore Holdings plc's fiscal Q1 earnings report was released on Wednesday, February 25. Let's dive in to see if (IMCR) missed or beat analyst's expectations.Omar Beirat
Financial Summary
| Share Statistics | IMCR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,873.0 | $286.3 | 52% |
|
| Shares Out (Mil) | 51.0 | 54.2 | 48% |
|
| Institutional Ownership | 99.9% | 92.8% | 96% |
|
| Float (Mil) | 45.8 | 39.7 | 45% |
|
| Beta | 0.74 | 0.94 | 44% |
|
| Avg Daily Volume (000s) | 410 | 534 | 55% |
|
| Price Change (52-week) |
12.5% | 58.7% | 56% |
|
| Growth | IMCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 57.6% | 13.6% | 97% |
|
| Net Income (5yr) | 18.9% | (10.1%) | 71% |
|
| EPS (5yr) | 28.7% | 16.0% | 80 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.2%) | (15.6%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | na | 12 | |
| Current EPS | ($0.115) | na | ($0.746) | |
| Month Ago EPS | ($0.014) | na | ($0.625) | |
| # Rev Up | 1 | na | 1 | |
| # Rev Down | 0 | na | 0 | |
| Three Months Ago EPS | ($0.014) | na | ($0.674) | |
| Year/Year Chg | 475.0% | na | na | |
| Financials | IMCR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $431 | $37 | 39% |
|
| Net Income (TTM) (Mil) | ($18) | ($43) | 25% |
|
| EPS (TTM) | ($0.357) | ($1.400) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($35) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($3) | $2 | 36% |
|
| Long-Term Debt (Q1) (Mil) | $433 | $4 | 57% |
|
| Enterprise Value (Q1) (Mil) | $1,305 | $160 | 44% |
|
| Valuation | IMCR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.46 | 2.77 | 75% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | IMCR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 32.9% | 64.2% | 39% |
|
| Net Margin | (4.2%) | (75.9%) | 26% |
|
| ROA | (1.6%) | (47.3%) | 35% |
|
| ROE | (4.5%) | (55.0%) | 31% |
|
| Liabilities to Assets | 62.5% | 29.6% | 57% |
|
| F-Score | 3 | 2 | 18% |
|
Immunocore Holdings plc did not pass any screens on 8/20/2026.
